Absorbed dose is the amount of energy deposited by ionising radiation per unit mass of tissue. It is measured in gray (Gy), where 1 Gy equals one joule of energy absorbed per kilogram of tissue. Absorbed dose is a fundamental quantity in both radiation protection and radionuclide therapy, as it determines the biological effect of radiation on a given tissue. It should be distinguished from activity (the quantity of radioactive material administered) and from the pharmacological concept of dose (the amount of a drug given): the absorbed dose received by a tissue depends not only on the activity administered, but also on how the radiopharmaceutical distributes and is retained in the body.
About us
What is nuclear medicine?
Find out what nuclear medicine is all about!
Definition
Nuclear medicine is a multi-professional, independent, medical discipline based on the application of probes labelled with radionuclides (radiopharmaceuticals) to both diagnose and treat various diseases. Its scope encompasses molecular imaging, image-guided procedures, and targeted radionuclide therapy.
Using radiopharmaceuticals, nuclear medicine procedures target specific physio-pathological processes or features underlying a disease directly at the molecular level. Using advanced hybrid equipment (i.e., combination with radiological imaging, SPECT/CT and PET/CT, or PET/MRI) the functional data obtained from nuclear medicine is combined with information obtained by CT and MRI. This multimodal approach ensures a comprehensive diagnostic map, fostering precision medicine to diagnose, prognosticate, administer targeted therapy, guide treatment, and monitor its effects.
Theranostics is a specific branch of nuclear medicine which combines diagnostic imaging and targeted therapy by selecting the used radionuclide according to its radiation properties. The use of a diagnostic radiopharmaceutical enables the selection of patients for a subsequent treatment by targeting a specific molecular feature of the disease. The matched therapeutic agent, targeting the very same feature, is a radiopharmaceutical as well. Thus, such pairs of radiolabelled compounds, the radiotheranostics, are used to ‘see what we treat’ and ‘treat what we see’.
Recommended in clinical guidelines, several nuclear medicine procedures implementing state-of-the-art clinical standards are currently available to enhance patient care worldwide, for both diagnostic and therapeutic applications. The nuclear medicine discipline is defined by its commitment to quality improvement, technological innovation, stringent safety standards for radiation protection, and thorough health technology evaluations to safeguard both medical staff and patients.
Furthermore, nuclear medicine plays a pivotal role in biomedical research by facilitating the accelerated development of new drugs, especially in early-phase clinical trials. The application of total-body imaging, the reliance on AI-supported deep data analysis, and the implementation of true non-invasive network medicine are paving the way for the future of medical treatment standards.
As an umbrella organisation representing healthcare professionals working in nuclear medicine, EANM is devoted to promoting a safe, sustainable, and accessible use of radiopharmaceuticals. EANM is cooperating with major medical societies from other clinical fields to ensure a safe and equal access to healthcare for all patients across Europe. A special focus is dedicated to nurturing the next generation of nuclear medicine physicians, medical physicists, radiochemists, pharmacists, and technologists to ensure the discipline’s continued advancements and its benefits to patient care.
Glossary
29 glossary terms displayed.
In nuclear medicine, activity refers to the quantity of a radioactive substance, expressed as the number of radioactive decay events occurring per unit of time. It is measured in becquerels (Bq), or more commonly in clinical practice in megabecquerels (MBq). Activity is the quantity that is measured and prescribed when administering a radiopharmaceutical to a patient. It should not be confused with the term “dose” as used in conventional pharmacology, where it refers to the amount of a drug administered.
Biomarker quantification refers to the automated, quantitative measurement of biological signals derived from imaging or other data sources, such as tracer uptake/expression or metabolic activity, for example, the expression of targets such as PSMA or somatostatin receptors (SSTR). Unlike MRI, which typically provides relative signal intensity, nuclear medicine imaging (PET/SPECT) can provide quantitative or semi-quantitative measures of tracer distribution or uptake, and, under appropriate calibration and modelling conditions, estimates of activity concentration or kinetic parameters. This provides an objective and measurable indicator of disease status, treatment response or physiological function.
Professionals from adjacent medical disciplines, who collaborate with the nuclear medicine team to ensure that nuclear medicine findings are interpreted and applied within the broader context of a patient’s diagnosis and treatment.
A cyclotron is a type of particle accelerator used to produce radionuclides for medical use. It works by accelerating charged particles to high speeds and directing them to a target material, triggering nuclear reactions that generate the desired radionuclide. Cyclotrons are commonly used to produce diagnostic PET tracers such as 18F and 11C. Because cyclotrons can be installed locally, they allow short-lived PET tracers to be distributed directly to nearby PET centres before they decay.
Dosimetry is the calculation and measurement of the radiation dose absorbed by a patient’s tissue. The dose delivered by a radiopharmaceutical depends on individual factors, such as how much of it accumulates in a given tissue and how long it stays there. Accurate dosimetry ensures that treatments reach the target tissue effectively while keeping exposure to healthy organs within safe limits.
Endpoint adjudication is the standardised and often blinded evaluation of clinical trial outcomes, such as tumour response or disease progression, against pre-defined criteria. It ensures consistent and objective classification of results across trial sites.
Hybrid imaging describes Nuclear Medicine imaging modalities that are based on SPECT or PET machines that are combined with other imaging modalities’ scanners (such as computed tomography CT or magnetic resonance MR) to enrich the functional imaging properties of Nuclear Medicine with the anatomical information of those modalities in one scan procedure for the patient. Similarly to the above, expressions like PET/CT, PET/MR, SPECT/CT, etc. describe both the hybrid imaging procedure as well as the equipment that is needed to obtain the patient scans.
Ionising radiation is a type of energy released by atoms that travels in the form of electromagnetic waves (gamma or X-rays) or particles (neutrons, beta or alpha). Ionising radiation is used in the medical field for diagnosis and treatment. Today, the most common human-made sources of ionising radiation are medical devices, including X-ray machines.
Lesion segmentation refers to the automated identification and delineation of abnormal tissue areas (such as tumours or metastases) within medical images, enabling reproducible measurement of lesion size, volume and distribution across imaging time points.
Scientists with advanced expertise in the application of physics to medicine. In nuclear medicine, they are responsible for ensuring the safety, accuracy, and quality of both imaging and therapeutic procedures. Their role includes performing dosimetry calculations to optimise radiation doses in therapy, and implementing radiation protection measures to safeguard patients, staff, and the public.
Medical doctors with specialist training in nuclear medicine. They are responsible for the clinical management of patients undergoing nuclear medicine procedures, including selecting the appropriate diagnostic or therapeutic approach, prescribing radiopharmaceuticals, interpreting imaging results, and integrating findings into the patient’s overall care pathway.
Appropriate delivery of Nuclear Medicine services requires multidisciplinarity with the involvement of various professionals, including Nuclear Medicine physicians, Nuclear Medicine physicists, radiopharmacists, radiochemists and Nuclear Medicine technologists as well as others.
Positron emission tomography (PET) is a Nuclear Medicine procedure utilising positrons to depict body-internal biological processes – the imaging procedure resulting in the so-called PET scan of the patient. Also, commonly referring to the device/machine that is used to produce these scans. The use of PET and SPECT depends on the kind of particle/radiation emitted by the radionuclide.
Radiation protection refers to the set of measures, principles, and practices designed to limit exposure to ionising radiation for patients, healthcare workers, and the general public. It follows the ALARA principle, keeping radiation exposure As Low As Reasonably Achievable.
A radiation safety officer is a professional responsible for overseeing and implementing the radiation protection programme within a nuclear medicine facility or broader healthcare institution. Their role includes ensuring compliance with national and international radiation safety regulations, monitoring radiation exposure of staff, managing radioactive waste, and advising on safe handling procedures for radioactive materials.
Radioactivity is the property of certain atoms whose nuclei are unstable and spontaneously release energy in the form of radiation. This process, called radioactive decay, transforms the atom into a more stable form. Radioactivity occurs naturally in some elements and can also be induced artificially. Different types of radiation are used for different purposes in nuclear medicine: particle radiation (such as alpha or beta particles), which deposits its energy over a short range, is generally used for therapy; photon radiation (such as gamma rays), which can travel further and be detected from outside the body, is generally used for diagnostic imaging.
Specialists responsible for the design, synthesis, and preparation of radiopharmaceuticals. Radiochemists typically focus on the development of new radiolabelled compounds and production processes, while radiopharmacists oversee the preparation, quality control, and dispensing of radiopharmaceuticals for clinical use.
Radiolabelling is the process of attaching a radionuclide to a biological molecule, drug, or other chemical compound to create a radiopharmaceutical. The resulting labelled compound retains its biological behaviour, allowing it to be tracked within the body for diagnostic imaging or to deliver a therapeutic radiation dose to a specific target.
A radionuclide is an atom with an unstable nucleus that releases energy through radioactive decay; when referring specifically to an unstable variant of a particular chemical element, it is also called a radioisotope. In practice, the two terms are used interchangeably in nuclear medicine. Radionuclides are produced in nuclear reactors, cyclotrons, or generators and are used to make radiopharmaceuticals. The most common radionuclide used in Nuclear Medicine is technetium-99m (99mTc).
A radiopharmaceutical is a drug that contains a radioactive substance, used to diagnose or treat diseases. It consists of two parts: a radionuclide and a vector molecule that directs it to its target in the body. When a radiopharmaceutical is administered in a very small, pharmacologically inactive quantity for diagnostic purposes, it may be referred to as a tracer (or radiotracer), although this term commonly refers to diagnostic use and is not applied to therapeutic radiopharmaceuticals. Because PET and SPECT imaging are highly sensitive, only a tiny amount of radioactivity is needed to visualise biological processes such as metabolic activity, blood flow, or receptor distribution, thus keeping radiation exposure to the patient very low.
Within a hospital, radiopharmacy requires a dedicated space, respecting radiation protection requirements, where Nuclear Medicine radiopharmacists prepare radioactive materials for patient administration.
Professionals who provide dedicated patient care before, during, and after nuclear medicine procedures. They support patients through diagnostic and therapeutic pathways, manage clinical follow-up, coordinate care across specialties, and offer guidance on radiation safety precautions relevant to patients and their families.
Single photon emission computed tomography (SPECT) is a Nuclear Medicine procedure using single photons to depict body-internal biological processes. Tomographic images are acquired using gamma cameras, resulting in the so-called SPECT scan of the patient. Also, commonly used to refer to the device/machine that is employed to produce these scans.
Transarterial radioembolisation (TARE), also known as selective internal radiation therapy (SIRT), uses radioactive microspheres or resins (such as Yttrium-90-labelled microspheres). They are injected into the arterial supply of liver tumours to deliver localised therapeutic beta radiation to target lesions, while reducing radiation exposure to surrounding healthy liver tissue.
Targeted Radionuclide Therapy (TRT), also known as radiopharmaceutical therapy, molecular radiotherapy, or endoradiotherapy, is a systemic, targeted therapy that uses radiopharmaceuticals / unsealed radioactive sources (sources not contained within a fixed casing, and therefore free to move within the body after administration). It combines a vector molecule that binds to disease cells with a radionuclide that emits therapeutic radiation to destroy them. TRT can be applied to many cancers, including neuroendocrine tumours, thyroid cancer, prostate cancer, and lymphoma. Radioligand therapy (RLT) is a specific form of TRT in which the vector molecule is a ligand that binds to a defined molecular target on cancer cells.
Healthcare professionals trained to operate nuclear medicine imaging equipment, administer radiopharmaceuticals to patients, provide radiation protection advice, and manage comprehensive patient care.
Theranostics is a term derived from a combination of therapeutics and diagnostics. It is used in Nuclear Medicine to describe the possibility of both diagnosing and treating a disease by targeting the same biological pathway, often using the same or closely related vector molecule, to ensure the best patient outcome.
A vector molecule is the component of a radiopharmaceutical that carries the radionuclide to its target in the body. It can be a peptide, a small molecule, an antibody, or another carrier, selected for its ability to bind selectively to receptors or structures associated with a specific disease, such as a tumour type. In simple terms: a radiopharmaceutical = a radionuclide + a vector molecule. When the vector molecule is a peptide, this approach is used in peptide receptor radionuclide therapy (PRRT).
Would you like to learn more?
EANM has been collaborating with its partners to effectively explain the fundamentals of nuclear medicine. Explore the following resources to learn more:
The Sunny & Tim video series, created by Dutch nuclear physician Ronald van Rheenen, also known as the ‘Photo Doctor,’ has achieved countless success stories. Through his visual patient education materials, he provides basic medical knowledge in a clear and accessible way. By adding a sense of adventure, these materials resonate with children and significantly reduce the initial fear often associated with medical examinations.
Nuclear Medicine Europe (NMEU) has developed a comprehensive website packed with resources, including informative content, animation videos, and educational materials to help you learn more about Nuclear Medicine.